As part of our responsibility to protect citizens from the impact of infectious diseases, the UK Health Security Agency (UKHSA) carries out surveillance activities across a range of pathogens which represent a significant risk to health. This involves multiple UKHSA teams working with external partners across a wide range of activities. Our assessments of the effectiveness of surveillance are incorporated into annual reports on surveillance and progress towards the elimination of notifiable diseases, including tuberculosis and measles.

Health Protection (Notification) Regulations 2010 serve an important role in England’s ability to respond promptly to suspected cases of infectious disease that could have an impact on public health, by supporting a robust surveillance system. Regulations are reviewed by the Department and UKHSA, and include public consultations. A summary of responses to the recent Health Protection (Notification) Regulations 2010: proposed amendments consultation, is available at the following link:

https://www.gov.uk/government/consultations/health-protection-notification-regulations-2010-proposed-amendments/public-feedback/summary-of-responses-to-the-health-protection-notification-regulations-2010-proposed-amendments-consultation

Further work is being undertaken by the UK Health Security Agency (UKHSA) to explore reasons why people may not be offered or decline the offer of an HIV test in Sexual Health clinics. UKHSA will provide a descriptive analysis of predictors in the third quarter of 2024.

A late HIV diagnoses steering group will be held in the second quarter of 2024 to review and agree the content of the protocol. Software is also under development to enable information to be captured.

Further analyses around HIV acquisitions will be undertaken to ensure the circumstances reflect a wide range of people living with HIV. This will be published in the third quarter of 2024.

Early years entitlement funding is one of the funding blocks of the Dedicated Schools Grant (DSG). The latest information regarding early years funding is available at: https://www.gov.uk/government/publications/early-years-funding-2023-to-2024.

As part of the annual Section 251 budget return, local authorities return data on their planned early years spending for the next financial year, which is then published by the department. The latest published planned expenditure data is for the 2022/23 financial year and is available at: https://explore-education-statistics.service.gov.uk/find-statistics/planned-la-and-school-expenditure.

The data collection process for planned expenditure data for the 2023/24 financial year is ongoing and will be published in the autumn of 2023. Local authorities also submit less detailed outturn data regarding spend which is published by the department. The latest available outturn data is for the 2021/22 financial year and can be found in the file named ‘LA expenditure on schools, other education and community’ at: https://explore-education-statistics.service.gov.uk/data-catalogue/la-and-school-expenditure/2021-22.

Early years funding is one of the funding blocks of the dedicated schools grant (DSG). Whilst the department does collect information around the total level of DSG underspend from local authorities, specific information regarding which funding blocks within the DSG the underspends have originated from is not collected.

People living with human immunodeficiency virus (HIV) who meet the relevant criteria can access emtricitabine and tenofovir alafenamide (Descovy®) through the NHS England clinical commissioning policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents, which is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2017/03/f03-taf-policy.pdf

As part of the human immunodeficiency virus (HIV) Action Plan, we committed to optimising access to treatment and retention and re-engagement in HIV care. As part of the HIV Action Plan Implementation Steering Group, which drives forward the implementation of the Plan, we established a retention and re-engagement in care Task and Finish subgroup including UK Health Security Agency, British HIV Association and other key stakeholders who will provide advice on how to increase the number of people retained and re-engaged in care and receive effective medical care. The Implementation Steering Group will be considering the advice and, if needed, take appropriate action to ensure we meet our Action Plan’s objectives.

All pregnant women receive a Personalised Care and Support Plan, which is a series of facilitated conversations in which the person actively gets involved to explore the management of their health and well-being, taking into account individual needs and requirements, including pre-existing health conditions.

Further to this, NHS England have developed 14 Maternal Medicine Networks across England, to ensure that all women with chronic and acute medical problems around pregnancy, including diabetes, have access to specialist management and care from physicians and obstetrics.

With relation to human immunodeficiency virus (HIV), the Specialised Adult HIV Service Specification sets out the requirements for service providers to support the appropriate management of people living with HIV, including pregnant women with HIV, through referral to and liaison with primary care for management of non-HIV care needs. Service providers are required to ensure that pathways are in place for access to other specialties.

Section 31 of the Health and Care Act 2022 introduced duties on the Care Quality Commission to conduct reviews and assessments of integrated care systems. The government is preparing to make a Commencement Statutory Instrument that will commence these duties on 1 April 2023.

Sixth-form colleges have been eligible to bid into all rounds of the Post-16 Capacity Fund to date, for a share of £238 million to increase the capacity of their estate due to demographic increases in the local 16-19 population. The current bidding round, which will distribute funding secured in this spending review period, closes on 11 November 2022.

Funding beyond this spending review period is subject to consideration in future spending reviews.

Sixth-form colleges are also eligible to bid to the Condition Improvement Fund (CIF) for estate expansion projects. The CIF 2023/24 application round is currently open for applications, and eligible sixth form colleges have been invited to submit an application.

We continue to work with the UK Health Security Agency, local authorities and NHS England to monitor the impact of monkeypox on sexual health services and maintain access to routine sexual and reproductive health (SRH) services, including HIV pre-exposure prophylaxis and contraception.

We have allocated more than £3 billion to local authorities in England to fund public health services, including SRH services, through the Public Health Grant in 2022/23. It is for individual local authorities to determine spending priorities based on an assessment of local need, including for SRH services. In addition, we have provided funding for antiviral medicines to treat monkeypox, the procurement of the smallpox vaccine and for sexual health services to deliver this vaccine to those eligible for vaccination.

We continue to work with the UK Health Security Agency, local authorities and NHS England to monitor the impact of monkeypox on sexual health services and maintain access to routine sexual and reproductive health (SRH) services, including HIV pre-exposure prophylaxis and contraception.

We have allocated more than £3 billion to local authorities in England to fund public health services, including SRH services, through the Public Health Grant in 2022/23. It is for individual local authorities to determine spending priorities based on an assessment of local need, including for SRH services. In addition, we have provided funding for antiviral medicines to treat monkeypox, the procurement of the smallpox vaccine and for sexual health services to deliver this vaccine to those eligible for vaccination.

We continue to work with the UK Health Security Agency, local authorities and NHS England to monitor the impact of monkeypox on sexual health services and maintain access to routine sexual and reproductive health (SRH) services, including HIV pre-exposure prophylaxis and contraception.

We have allocated more than £3 billion to local authorities in England to fund public health services, including SRH services, through the Public Health Grant in 2022/23. It is for individual local authorities to determine spending priorities based on an assessment of local need, including for SRH services. In addition, we have provided funding for antiviral medicines to treat monkeypox, the procurement of the smallpox vaccine and for sexual health services to deliver this vaccine to those eligible for vaccination.

HM Government is committed to implementing the rights of way reform package as soon as reasonably practicable in 2023 and is working closely with the Stakeholder Working Group in finalising the individual measures. The 2026 cut-off date will be repealed as soon as a suitable legislative vehicle has been identified.

We are actively considering options for legislating to change the inflationary index to the Consumer Price Index, including through supporting a Private Member's Bill in this Session.

The Government continues to be guided by the advice of the independent Joint Committee on Vaccination and Immunisation (JCVI) on COVID-19 vaccinations.

On 15 July 2022, the Government accepted the JCVI’s advice to offer an autumn booster vaccination to increase immunity in those at higher risk from COVID-19 and protect against severe illness, hospitalisation and death in winter 2022/23. The booster dose will be offered to residents and staff in a care home for older adults; all adults aged 50 years old and over; those aged five to 49 years old in a clinical risk group or who are household contacts of someone with immunosuppression; frontline health and social care workers; and carers aged 16 years old and over.

The UK has a long-standing partnership with the Global Fund, investing £4.1 billion to date. We are the second largest donor of the 6th replenishment. The Global Fund remains an essential partner for the UK in the fight against HIV, TB and malaria. We will continue to work and engage with our allies in the G7, G20, and the Commonwealth to encourage support of the Global Fund's 7th replenishment and to strengthen health systems. We have been supporting the German G7 Presidency to ensure a sustained G7 commitment to the Global Fund and are working with the Indonesian G20 Presidency to support its focus on TB financing which includes a successful Global Fund replenishment.

Countries made significant commitments at COP26 on emissions reductions; finance and support for developing nations; and adaptation, loss and damage. We are continuing to press countries

to deliver on their promises. Together with the COP27 presidency of Egypt, I will next month be co-chairing a meeting of a representative group of Ministers from around the world, hosted by the Danish Government, to take stock of progress on the delivery of the Glasgow climate pact.